MNMD
Price
$6.21
Change
+$0.10 (+1.64%)
Updated
Apr 24, 02:39 PM (EDT)
Capitalization
437.14M
20 days until earnings call
NGNE
Price
$15.06
Change
-$0.38 (-2.46%)
Updated
Apr 24, 02:38 PM (EDT)
Capitalization
197.24M
Ad is loading...

MNMD vs NGNE

Header iconMNMD vs NGNE Comparison
Open Charts MNMD vs NGNEBanner chart's image
Mind Medicine (MindMed)
Price$6.21
Change+$0.10 (+1.64%)
Volume$261
Capitalization437.14M
Neurogene
Price$15.06
Change-$0.38 (-2.46%)
Volume$400
Capitalization197.24M
MNMD vs NGNE Comparison Chart
Loading...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NGNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MNMD vs. NGNE commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNMD is a StrongBuy and NGNE is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (MNMD: $6.09 vs. NGNE: $15.46)
Brand notoriety: MNMD and NGNE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNMD: 64% vs. NGNE: 119%
Market capitalization -- MNMD: $437.14M vs. NGNE: $197.24M
MNMD [@Biotechnology] is valued at $437.14M. NGNE’s [@Biotechnology] market capitalization is $197.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNMD’s FA Score shows that 1 FA rating(s) are green whileNGNE’s FA Score has 0 green FA rating(s).

  • MNMD’s FA Score: 1 green, 4 red.
  • NGNE’s FA Score: 0 green, 5 red.
According to our system of comparison, MNMD is a better buy in the long-term than NGNE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNMD’s TA Score shows that 5 TA indicator(s) are bullish while NGNE’s TA Score has 5 bullish TA indicator(s).

  • MNMD’s TA Score: 5 bullish, 4 bearish.
  • NGNE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both MNMD and NGNE are a good buy in the short-term.

Price Growth

MNMD (@Biotechnology) experienced а +11.54% price change this week, while NGNE (@Biotechnology) price change was +43.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.04%. For the same industry, the average monthly price growth was -8.89%, and the average quarterly price growth was -12.57%.

Reported Earning Dates

MNMD is expected to report earnings on Aug 14, 2025.

NGNE is expected to report earnings on Nov 14, 2023.

Industries' Descriptions

@Biotechnology (+8.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNMD($437M) has a higher market cap than NGNE($197M). MNMD YTD gains are higher at: -12.500 vs. NGNE (-32.371). NGNE has higher annual earnings (EBITDA): -49.96M vs. MNMD (-105.87M). MNMD has more cash in the bank: 274M vs. NGNE (139M). NGNE has less debt than MNMD: NGNE (14.5M) vs MNMD (21.9M). NGNE has higher revenues than MNMD: NGNE (925K) vs MNMD (0).
MNMDNGNEMNMD / NGNE
Capitalization437M197M222%
EBITDA-105.87M-49.96M212%
Gain YTD-12.500-32.37139%
P/E RatioN/AN/A-
Revenue0925K-
Total Cash274M139M197%
Total Debt21.9M14.5M151%
FUNDAMENTALS RATINGS
MNMD vs NGNE: Fundamental Ratings
MNMD
NGNE
OUTLOOK RATING
1..100
314
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
65
Fair valued
PROFIT vs RISK RATING
1..100
96100
SMR RATING
1..100
9594
PRICE GROWTH RATING
1..100
7986
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNMD's Valuation (32) in the null industry is somewhat better than the same rating for NGNE (65). This means that MNMD’s stock grew somewhat faster than NGNE’s over the last 12 months.

MNMD's Profit vs Risk Rating (96) in the null industry is in the same range as NGNE (100). This means that MNMD’s stock grew similarly to NGNE’s over the last 12 months.

NGNE's SMR Rating (94) in the null industry is in the same range as MNMD (95). This means that NGNE’s stock grew similarly to MNMD’s over the last 12 months.

MNMD's Price Growth Rating (79) in the null industry is in the same range as NGNE (86). This means that MNMD’s stock grew similarly to NGNE’s over the last 12 months.

MNMD's P/E Growth Rating (100) in the null industry is in the same range as NGNE (100). This means that MNMD’s stock grew similarly to NGNE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNMDNGNE
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 21 days ago
86%
Bearish Trend 17 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NGNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GIDAX7.54N/A
N/A
Goldman Sachs Intl Eq Div & Prem A
HSZAX4.97N/A
N/A
NexPoint Climate Tech A
DURPX22.53N/A
N/A
DFA US Hi Relatv Profitability Instl
EMGEX6.85N/A
N/A
Emerging Markets Growth Fund F-3
SUIRX53.57N/A
N/A
DWS CROCI International R6

MNMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNMD has been loosely correlated with ATAI. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MNMD jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNMD
1D Price
Change %
MNMD100%
+5.00%
ATAI - MNMD
51%
Loosely correlated
+3.74%
LABFF - MNMD
47%
Loosely correlated
N/A
BEAM - MNMD
46%
Loosely correlated
+3.87%
EYPT - MNMD
46%
Loosely correlated
+3.15%
RGNX - MNMD
46%
Loosely correlated
+13.43%
More

NGNE and

Correlation & Price change

A.I.dvisor indicates that over the last year, NGNE has been loosely correlated with BRNS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NGNE jumps, then BRNS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGNE
1D Price
Change %
NGNE100%
+11.79%
BRNS - NGNE
51%
Loosely correlated
+8.02%
RNAZ - NGNE
48%
Loosely correlated
+1.96%
SNDX - NGNE
48%
Loosely correlated
+0.62%
ZNTL - NGNE
45%
Loosely correlated
+1.70%
MNMD - NGNE
44%
Loosely correlated
+5.00%
More